Our laboratory has been engaged in studies to determine the signal transduction pathway by which naturally occurring oxysterols induce apoptosis in various vascular cells, particularly macrophages. Our published results indicate that arachidonyl esters of these oxysterols are second messengers of the apoptotic response. In an effort to understand the mechanism by which these compounds entrain apoptosis we have begun to examine the hypothesis that arachidonyl oxysterols produce these effects via the cannabinoid 2 (CB2) receptor. Preliminary findings, presented in this proposal, of a loss of the apoptotic response to oxysterol treatment in various cell models defective in CB2 signaling are consistent with this hypothesis. Other studies from our laboratory indicate that one of the physiologically significant consequences of macrophage apoptosis in response to oxysterols is as a protective mechanism against atherosclerosis. This raises the possibility that CB2 signaling of apoptosis in macrophages may serve as one of the signaling pathways of this anti-atherosclerotic effect. To test these ideas regarding the mechanism and physiological significance of arachidonyl oxysterol signaling of apoptosis in macrophages we propose the following specific aims: 1) Determine if arachidonyl oxysterols can induce apoptosis in macrophages. 2) Determine if arachidonyl oxysterols can bind to cannabinoid receptors and modulate their activity. 3) Examine the role of the CB2 receptor in the development of atherosclerosis in mouse models. The results from this investigation may expand our understanding of the link between cannabinoid signaling mechanisms and the mechanisms regulating apoptosis in macrophages. They may also provide new pharmacologically exploitable targets for the development of novel pharmaceuticals for treatment of atherosclerosis. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Academic Research Enhancement Awards (AREA) (R15)
Project #
1R15HL085137-01
Application #
7128044
Study Section
Membrane Biology and Protein Processing (MBPP)
Program Officer
Wassef, Momtaz K
Project Start
2006-08-15
Project End
2009-07-31
Budget Start
2006-08-15
Budget End
2009-07-31
Support Year
1
Fiscal Year
2006
Total Cost
$219,000
Indirect Cost
Name
East Tennessee State University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
051125037
City
Johnson City
State
TN
Country
United States
Zip Code
37614
Netherland-Van Dyke, Courtney; Rodgers, Ward; Fulmer, Makenzie et al. (2015) Cannabinoid Receptor Type 2 (CB2) Dependent and Independent Effects of WIN55,212-2 on Atherosclerosis in Ldlr-null Mice. J Cardiol Ther 3:53-63
Netherland, Courtney D; Pickle, Theresa G; Bales, Alicia et al. (2010) Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis 213:102-8
Netherland, Courtney; Thewke, Douglas P (2010) Rimonabant is a dual inhibitor of acyl CoA:cholesterol acyltransferases 1 and 2. Biochem Biophys Res Commun 398:671-6
Liu, June; Netherland, Courtney; Pickle, Theresa et al. (2009) Stimulation of Akt poly-ubiquitination and proteasomal degradation in P388D1 cells by 7-ketocholesterol and 25-hydroxycholesterol. Arch Biochem Biophys 487:54-8
Thewke, Douglas; Freeman-Anderson, Natalie; Pickle, Theresa et al. (2009) AM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitors. Biochem Biophys Res Commun 381:181-6
Freeman-Anderson, Natalie E; Pickle, Theresa G; Netherland, Courtney D et al. (2008) Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis. J Lipid Res 49:2338-46